Concepedia

Medication Persistence Policy

Medication Persistence Policy is a health policy framework that specifies the duration and continuity of medication use by patients, distinguishing itself from related adherence policies through its focus on sustained treatment over time rather than initial uptake or dosing accuracy.

3

Publications

126

Citations

17

Authors

5

Institutions

Publications per year

2017–2026

1

Parents

Children

Publications

3

1–3 of 3

Authors

17

  1. RG
    Rahul Ganguly

    Novo Nordisk (United States), United States

    1 publications · 69 citations

    1

    h-index

  2. MH
    Malene Hersloev

    Novo Nordisk (United States), United States

    1 publications · 69 citations

    1

    h-index

  3. SS
    Shilpa Shah-Mehta

    Novartis (United States), United States

    1 publications · 45 citations

    1

    h-index

  4. AF
    Arrigo F.G. Cicero

    University of Bologna, Italy

    1 publications · 12 citations

    1

    h-index

  5. GD
    Giuseppe Derosa

    University of Pavia, Italy

    1 publications · 12 citations

    1

    h-index

1–5 of 17

Institutions

5

  1. IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola

    Bologna, Italy

    1 h-index

    1 publications

    12 citations

  2. Novo Nordisk (United States)

    Seattle, United States

    1 h-index

    8 publications

    552 citations

  3. Novo Nordisk (Denmark)

    Copenhagen, Denmark

    1 h-index

    1 publications

    69 citations

  4. Novartis (United States)

    New York, United States

    1 h-index

    3 publications

    135 citations

  5. University of Bologna

    Bologna, Italy

    1 h-index

    5 publications

    60 citations

1–5 of 5

Venues

  1. Atherosclerosis

    1 publications · 12 citations

    1

    h-index

  2. Diabetes Research and Clinical Practice

    1 publications · 69 citations

    1

    h-index

  3. Journal of Oncology Practice

    JOP · 1 publications · 45 citations

    1

    h-index

1–3